Partner Rebecca Dandeker spoke with BioWorld about the US Food and Drug Administration’s (FDA’s) Orange Book, which is approaching its 40th birthday this year. Rebecca, who is quoted extensively throughout the piece, discussed how the publication’s use has evolved and what companies can expect from it in the years ahead.
Read the full BioWorld article >>
Subscription may be required.